2696 — Shanghai Henlius Biotech Income Statement
0.000.00%
Last trade - 00:00
- HK$8.05bn
- HK$11.41bn
- CNY5.39bn
- 39
- 34
- 90
- 57
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 90.9 | 588 | 1,682 | 3,215 | 5,395 |
Cost of Revenue | |||||
Gross Profit | 19.1 | 405 | 1,160 | 2,370 | 3,919 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 917 | 1,537 | 2,554 | 3,803 | 4,715 |
Operating Profit | -827 | -950 | -872 | -588 | 680 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -875 | -994 | -957 | -694 | 570 |
Provision for Income Taxes | |||||
Net Income After Taxes | -875 | -994 | -984 | -695 | 546 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -875 | -994 | -984 | -695 | 546 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -875 | -994 | -984 | -695 | 546 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.73 | -1.87 | -1.79 | -1.28 | 1 |